Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 7Colorectal Neoplasms 4Colonic Neoplasms 2Anus Neoplasms 2Adenomatous Polyposis Coli 2HIV Infections 1Colorectal Adenoma 1Anal Canal Carcinoma 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Nivolumab 3Watchful Waiting 2Light Coagulation 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Fluorouracil 2Biopsy 2pembrolizumab 1dehydroftorafur 1cabozantinib 1Vorinostat 1Taxes 1Sigmoidoscopy 1Sentinel Lymph Node Biopsy 1Raltegravir Potassium 1Radiotherapy, Intensity-Modulated 1Proctoscopy 1Papanicolaou Test 1Paclitaxel 1Observation 1Mitozytrex 1Mitomycin 1Mass Screening 1Laser Therapy 1Isotretinoin 1Ipilimumab 1Interferon alpha-2 1Imiquimod 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HIV Infections × Sigmoidoscopy × Gastrointestinal × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡